| Document |
Document Title |
|
JP2018172399A |
To provide compounds useful for treatment of HBV infection.The invention provides compounds having the general formula in the figure.SELECTED DRAWING: None
|
|
JP6417419B2 |
Disclosed are compounds of Formula (I): (I). Also disclosed are methods of using such compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowin...
|
|
JP2018531213A |
The present invention relates to inhibitors of histone deacetylase, particularly HDAC8, which are useful in the treatment of cancer and other diseases and disorders, and the synthesis and application of such inhibitors. The present inven...
|
|
JP6411342B2 |
The present invention relates to compound (I) or a salt thereof which has a ROR³t inhibitory action. In the formula (I), each symbol is as defined in the specification.
|
|
JP6409001B2 |
including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein A, R1, R2, R3, R4, R5, R6, R7, and R8 are defined herein.
|
|
JP6389477B2 |
The present invention provides a cationic lipid which can be used for nucleic acid delivery to a cytoplasm and which is possible to solve the problem of physical stability of a lipid complex. This cationic lipid is a compound represented...
|
|
JP2018525342A |
Compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (eg, HDAC1, HDAC2, and HDAC3) are provided herein.
|
|
JP6385352B2 |
Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a su...
|
|
JP6382403B2 |
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including,e.g., in the treatment or prevention of cancer, a ne...
|
|
JP6382997B2 |
The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and composition.
|
|
JP2018123124A |
To provide compounds that have agonist activity for one or more of the S1P receptors, the compounds being sphingosine analogs that act as agonists for S1P receptors after phosphorylation and have enhanced potency, selectivity, and oral b...
|
|
JP2018521021A |
The present invention is in formula I(In the formula, ASC is -N (R8) (R9) ASC-1, and ASC-1 isRing A represents a 4- to 6-membered saturated ring containing a carbon atom as a ring member in addition to the nitrogen atom, where one CH2 po...
|
|
JP2018519245A |
Compounds of formula (I) that regulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds, and proliferative disorders using the compounds of the invention (eg, c...
|
|
JP6352950B2 |
This invention provides for a compound of formula (I):or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipid...
|
|
JP6347797B2 |
Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
|
|
JP2018516238A |
Compounds of formula (I) that regulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds, and proliferative disorders using the compounds of the invention (eg, c...
|
|
JP2018095561A |
To provide a highly efficient industrial production method of a diphenyl azetidine derivative which is a production raw material of a β-lactam derivative useful for the treatment and prevention of hypercholesterolemia such as arterioscl...
|
|
JP2018515438A |
Compounds that regulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds, and proliferative disorders (eg, cancer), viral infections and using the compounds of ...
|
|
JPWO2017038870A1 |
An object of the present invention is to provide a compound having an inhibitory activity on discoidin domain receptor 1. The present invention provides a urea derivative represented by the following formula or a pharmacologically accept...
|
|
JP6324380B2 |
Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
|
|
JP6321829B2 |
Disclosed is a new method for preparing an azetidinone compound represented by formula (I). The carboxylic ketoester represented by formula (II) serves as the raw material and is subjected to Grignard addition, stereoselective dehydratio...
|
|
JP2018510849A |
Disclosed are ester derivatives of sovetylom with enhanced CNS distribution.
|
|
JP2018058907A |
To provide a specific inhibitor of MEK useful for treatment of hyperproliferation-related disease (e.g., cancer) in mammal.A compound of a formula I and its salts and solvates which can be received pharmaceutically are MEK inhibitor and ...
|
|
JP6309519B2 |
The invention provides novel compounds having the general formula (I) and pharmaceutically acceptable salts thereof, wherein the variables RA, subscript n, ring A, X2, L, subscript m, X1, ring D, R1, and RN have the meaning as described ...
|
|
JP6306576B2 |
The invention is related to azetidinium-containing copolymers and vinylic monomers and their uses in formation of non-silicone hydrogel coatings on silicone hydrogel contact lenses.
|
|
JP6301842B2 |
A compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, has a TRPA1 antagonist activity, and the compound and a medicament containing the compound are useful for the prophylaxis or treatment of di...
|
|
JP6294872B2 |
Provided is a pharmaceutical composition which enables the inhibition of formation and/or enlargement of cerebral aneurysm or the regression of cerebral aneurysm. The pharmaceutical composition for the inhibition of formation and/or enla...
|
|
JP6258928B2 |
wherein R1, R2, Y and W are as described herein, compositions including the compounds and methods of using the compounds as autotaxin inhibitors.
|
|
JP6253823B2 |
This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compunds as at le...
|
|
JP6249076B2 |
The compound represented by the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high huma...
|
|
JP6240063B2 |
The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R 2a , R 2b , R 2c , R 5 and t are as described herein. The present invention rel...
|
|
JP6232384B2 |
The present invention relates to heterocyclic compounds useful for antagonizing angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their ...
|
|
JP6215212B2 |
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including,e.g., in the treatment or prevention of cancer, a ne...
|
|
JP2017165782A |
To provide a therapeutic compound and a composition.The present invention provides compounds and compositions that inhibit Factor XIa or kallikrein and methods of using these compounds and compositions. The present invention features com...
|
|
JP2017525677A |
The present invention is a compound having the general formula (I), in which the variable RA, RAA, Subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D, and E have the meanings described herein, and provide com...
|
|
JP6182594B2 |
The present invention is directed to novel retinoid-related orphan receptor gamma (RORγ) modulators, processes for their preparation, pharmaceutical compositions containing these modulators, and their use in the treatment of inflammator...
|
|
JP6177768B2 |
The present invention relates to benzamide derivatives represented by formula (I) or pharmaceutically acceptable salts thereof.
|
|
JP6169737B2 |
The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. X in formula (I) is selected from -OCF 3 and -OCH 3 . The other variables for Structural Formula (I) ar...
|
|
JP6153209B2 |
|
|
JP2017101071A |
To provide a specific inhibitor of MEK useful for treatment of hyperproliferation-related disease (e.g., cancer) in mammal.A compound of a formula I and its salts and solvates which can be received pharmaceutically are MEK inhibitor and ...
|
|
JP2017100990A |
To provide a novel production method for a trifluoromethane sulfonanilide compound.The present invention provides an industrially useful production method for N-alkoxycarbonyl-N-trifluoromethane sulfonanilide compound represented by the ...
|
|
JP2017081931A |
To provide antibacterial agents which can prevent infections cause by gram-negative bacteria, other compounds for use in the preparation of medicines and combinations of such compounds.The present invention provides a compound represente...
|
|
JP6130399B2 |
The invention relates to new azetidine derivatives of the formula I to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.
|
|
JP6130398B2 |
Azetidine derivatives of which the following is exemplary and their use in the treatment of obesity, diabetes or dyslipidemia.
|
|
JP6122006B2 |
In one aspect, the invention relates to substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of lysine-specific histone demethylase, including LSD1; s...
|
|
JP6117430B2 |
The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the ...
|
|
JP2017509609A |
To provide a novel phenylazetidine carboxylate or a carboxamide compound. The present invention relates to a compound of formula (I). [Chemical 1](In the formula, R, R1, R2, N, A and Cy are synonymous with the specification. ) The compou...
|
|
JPWO2015129859A1 |
To1Provided is a novel compound having a receptor antagonistic action. General formula (I): [Chemical 1] [In the formula, R1, R2And R3Are hydrogen atom, halogen atom, and C, respectively.1-6Alkyl group, halo C1-6Alkyl group, etc., R4Is C...
|
|
JP2017057206A |
To provide a method of treating pain of mammalian.There is provided a novel compound having the general formula (I), where variable R, subscript n, ring A, X, L, subscript m, X, B, R, R, R, R, Rand Rhave meanings described in the specifi...
|
|
JPWO2014203691A1 |
Provision of a platinum complex having an excellent antitumor effect and reduced toxicity such as myelosuppression and a drug containing the platinum complex. The following general equation (1) (in equation, R1And R2Indicates a hydrogen ...
|
